The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer

References

• SiegelRL, MillerKD, FuchsHE, JemalA. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.2165433433946
   PubMed Web of Science ®Google Scholar
• PerouCM, SørlieT, EisenMB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi:10.1038/3502109310963602
   PubMed Web of Science ®Google Scholar
• SørlieT, PerouCM, TibshiraniR, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–10874. doi:10.1073/pnas.19136709811553815
   PubMed Web of Science ®Google Scholar
• MontemurroF, ScaltritiM. Biomarkers of drugs targeting HER-family signalling in cancer. J Pathol. 2014;232(2):219–229. doi:10.1002/path.426924105684
   PubMed Web of Science ®Google Scholar
• MilaniA, MontemurroF, GioeniL, AgliettaM, ValabregaG. Role of trastuzumab in the management of HER2-positive metastatic breast cancer. Breast Cancer. 2010;2:93–109. doi:10.2147/BCTT.S607024367170
   PubMedGoogle Scholar
• BaselgaJ, CortésJ, KimS-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–119. doi:10.1056/NEJMoa111321622149875
   PubMed Web of Science ®Google Scholar
• BachelotT, CiruelosE, SchneeweissA, et al. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol. 2019;30(5):766–773. doi:10.1093/annonc/mdz06130796821
   PubMed Web of Science ®Google Scholar
• MontemurroF, Di CosimoS, ArpinoG. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol. 2013;24(11):2715–2724. doi:10.1093/annonc/mdt28723908178
   PubMed Web of Science ®Google Scholar
• VermaS, MilesD, GianniL, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. doi:10.1056/NEJMoa120912423020162
   PubMed Web of Science ®Google Scholar
• KropIE, KimS-B, González-MartínA, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, Phase 3 trial. Lancet Oncol. 2014;15(7):689–699. doi:10.1016/s1470-2045(14)70178-024793816
   PubMed Web of Science ®Google Scholar
• GiordanoSH, TeminS, DavidsonNE. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO Clinical Practice Guideline Update Summary. J Oncol Pract. 2018;14(8):501–504. doi:10.1200/JOP.18.0029029989839
   PubMed Web of Science ®Google Scholar
• WissnerA, MansourTS. The development of HKI‐272 and related compounds for the treatment of cancer. In: Archiv der Pharmazie; 2008;341(8):465–477. doi:10.1002/ardp.200800009.
   Google Scholar
• BaselgaJ, SwainSM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7):463–475. doi:10.1038/nrc265619536107
   PubMed Web of Science ®Google Scholar
• LinggiB, CarpenterG. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 2006;16(12):649–656. doi:10.1016/j.tcb.2006.10.00817085050
   PubMed Web of Science ®Google Scholar
• RabindranSK, DiscafaniCM, RosfjordEC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004;64(11):3958–3965. doi:10.1158/0008-5472.CAN-03-286815173008
   PubMed Web of Science ®Google Scholar
• RabindranSK. Antitumor activity of HER-2 inhibitors. Cancer Lett. 2005;227(1):9–23. doi:10.1016/j.canlet.2004.11.01516051028
   PubMed Web of Science ®Google Scholar
• CanoniciA, GijsenM, MulloolyM, et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013;4(10):1592–1605. doi:10.18632/oncotarget.114824009064
   PubMed Web of Science ®Google Scholar
• Wong-K-K, FracassoPM, BukowskiRM, et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res. 2009;15(7):2552–2558. doi:10.1158/1078-0432.CCR-08-197819318484
   PubMed Web of Science ®Google Scholar
• ItoY, SuenagaM, HatakeK, et al. Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study. Jpn J Clin Oncol. 2012;42(4):278–286. doi:10.1093/jjco/hys01222371427
   PubMed Web of Science ®Google Scholar
• BursteinHJ, SunY, DirixLY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28(8):1301–1307. doi:10.1200/JCO.2009.25.870720142587
   PubMed Web of Science ®Google Scholar
• MartinM, BonneterreJ, GeyerCE, et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer. 2013;49(18):3763–3772. doi:10.1016/j.ejca.2013.07.14223953056
   PubMed Web of Science ®Google Scholar
• SauraC, Garcia-SaenzJA, XuB, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2014;32(32):3626–3633. doi:10.1200/JCO.2014.56.380925287822
   PubMed Web of Science ®Google Scholar
• SauraC, OliveiraM, FengY-H, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-Positive metastatic breast cancer previously treated with ≥ 2 HER2-Directed Regimens: phase III NALA Trial. J Clin Oncol. 2020;38(27):3138–3149. doi:10.1200/JCO.20.0014732678716
   PubMed Web of Science ®Google Scholar
• Opleta-MadsenK, HardinJ, GallDG. Epidermal growth factor upregulates intestinal electrolyte and nutrient transport. Am J Physiol Gastrointest Liver Physiol. 1991;260(6):G807–G814. doi:10.1152/ajpgi.1991.260.6.g807
   Web of Science ®Google Scholar
• GoodladRA, RajaKB, PetersTJ, WrightNA. Effects of urogastrone-epidermal growth factor on intestinal brush border enzymes and mitotic activity. Gut. 1991;32(9):994–998. doi:10.1136/gut.32.9.9941680779
   PubMed Web of Science ®Google Scholar
• TaoZ, LiSX, ShenK, ZhaoY, ZengH, MaX. Safety and efficacy profile of neratinib: a systematic review and meta-analysis of 23 Prospective Clinical Trials. Clin Drug Investig. 2019;39(1):27–43. doi:10.1007/s40261-018-0719-0
   Web of Science ®Google Scholar
• UstarisF, SauraC, Di PalmaJ, et al. Effective management and prevention of Neratinib-induced diarrhea. Am J Hematol. 2015;11(11).
   Google Scholar
• MartinM, HolmesFA, EjlertsenB, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688–1700. doi:10.1016/S1470-2045(17)30717-929146401
   PubMed Web of Science ®Google Scholar
• ChanA, MoyB, MansiJ, et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer. 2020;21(1):80–91.e7. doi:10.1016/j.clbc.2020.09.01433183970
   PubMed Web of Science ®Google Scholar
• BarcenasCH, HurvitzSA, Di PalmaJA, et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol. 2020;31(9):1223–1230. doi:10.1016/j.annonc.2020.05.01232464281
   PubMed Web of Science ®Google Scholar
• TsukadaY, FouadA, PickrenJW, LaneWW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983;52(12):2349–2354. doi:10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B6640506
   PubMed Web of Science ®Google Scholar
• EvansAJ, JamesJJ, CornfordEJ, et al. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol. 2004;16(5):345–349. doi:10.1016/j.clon.2004.03.012
   Web of Science ®Google Scholar
• StemmlerHJ, KahlertS, SiekieraW, UntchM, HeinrichB, HeinemannV. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. 2006;15(2):219–225. doi:10.1016/j.breast.2005.04.01716026983
   PubMed Web of Science ®Google Scholar
• BrufskyAM, MayerM, RugoHS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17(14):4834–4843. doi:10.1158/1078-0432.CCR-10-296221768129
   PubMed Web of Science ®Google Scholar
• ClaytonAJ, DansonS, JollyS, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004;91(4):639–643. doi:10.1038/sj.bjc.660197015266327
   PubMed Web of Science ®Google Scholar
• SoffiettiR, AhluwaliaM, LinN, RudàR. Management of brain metastases according to molecular subtypes. Nat Rev Neurol. 2020;16(10):557–574. doi:10.1038/s41582-020-0391-x32873927
   PubMed Web of Science ®Google Scholar
• RamakrishnaN, TeminS, ChandarlapatyS, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(27):2804–2807. doi:10.1200/JCO.2018.79.271329939840
   PubMed Web of Science ®Google Scholar
• AwadaA, ColomerR, InoueK, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-Positive breast cancer: the NEfERT-T Randomized Clinical Trial. JAMA Oncol. 2016;2(12):1557–1564. doi:10.1001/jamaoncol.2016.023727078022
   PubMed Web of Science ®Google Scholar
• FreedmanRA, GelmanRS, AndersCK, et al. TBCRC 022: a Phase II Trial of Neratinib and Capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2019;37(13):1081–1089. doi:10.1200/JCO.18.0151130860945
   PubMed Web of Science ®Google Scholar
• MurthyRK, LoiS, OkinesA, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382(7):597–609. doi:10.1056/NEJMoa191460931825569
   PubMed Web of Science ®Google Scholar
• XuB, YanM, MaF, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(3):351–360. doi:10.1016/S1470-2045(20)30702-633581774
   PubMed Web of Science ®Google Scholar
• RugoHS, ImS-A, CardosoF, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-Positive advanced breast cancer: a phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7(4):573. doi:10.1001/jamaoncol.2020.793233480963
   PubMed Web of Science ®Google Scholar
• ModiS, SauraC, YamashitaT, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–621. doi:10.1056/NEJMoa191451031825192
   PubMed Web of Science ®Google Scholar
• BanerjiU, van HerpenCML, SauraC, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20(8):1124–1135. doi:10.1016/S1470-2045(19)30328-631257177
   PubMed Web of Science ®Google Scholar
• MuellerV, PaplomataE, HamiltonEP, et al. 275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM). Ann Oncol. 2020;31:S349–S350. doi:10.1016/j.annonc.2020.08.377
   Web of Science ®Google Scholar
• LinNU, BorgesV, AndersC, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB Trial. J Clin Oncol. 2020;JCO2000775.
   Web of Science ®Google Scholar
• LinNU, DiérasV, PaulD, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452–1459. doi:10.1158/1078-0432.CCR-08-108019228746
   PubMed Web of Science ®Google Scholar
• BachelotT, RomieuG, CamponeM, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group Phase 2 study. Lancet Oncol. 2013;14(1):64–71. doi:10.1016/S1470-2045(12)70432-123122784
   PubMed Web of Science ®Google Scholar
• RamakrishnaN, TeminS, ChandarlapatyS, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(19):2100–2108. doi:10.1200/JCO.2013.54.095524799487
   PubMed Web of Science ®Google Scholar
• CoccoE, Javier CarmonaF, RazaviP, et al. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Sci Signal. 2018;11(551):551. doi:10.1126/scisignal.aat9773
   Web of Science ®Google Scholar
• HymanDM, Piha-PaulSA, WonH, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554(7691):189–194. doi:10.1038/nature2547529420467
   PubMed Web of Science ®Google Scholar
• FreedmanRA, GelmanRS, WefelJS, et al. Translational Breast Cancer Research Consortium (TBCRC) 022: a Phase II Trial of Neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2016;34(9):945–952. doi:10.1200/JCO.2015.63.034326834058
   PubMed Web of Science ®Google Scholar
• MontemurroF, DelalogeS, BarriosCH, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol. 2020;31(10):1350–1358. doi:10.1016/j.annonc.2020.06.02032634611
   PubMed Web of Science ®Google Scholar
• JerusalemG, ParkYH, YamashitaT, et al. 138O CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses. Ann Oncol. 2020;31:S63–S64. doi:10.1016/j.annonc.2020.03.239
   Web of Science ®Google Scholar